Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Other than skin cancer, prostate cancer is the most common cancer in American men with about one in seven receiving a prostate cancer diagnosis during his lifetime.
The American Cancer Society’s 2016 estimates for prostate cancer in the United States are approximately 190,000 new cases diagnosed and over 26,000 deaths.
Thanks to early detection, prostate cancer is a survivable disease for many, download the white paper to find out more.
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
To build and maintain gold-standard, next generation R&D intelligence tools, Sitetrove, Trialtrove, Pharmaprojects, and Trialpredict have been undergoing a major program of investment. In addition to the many new and exciting changes on the horizon, the robust and reliable Citeline tools that you use to inform your business decisions will formally join Informa’s Pharma Intelligence family of brands.
The industry’s most trusted drug development database, Citeline's Pharmaprojects has been covering pharma R&D across global markets for 35+ years. With 68,000+ drug profiles including 15,000 drugs in active development, it’s the go-to resource for preclinical, clinical, and pipeline coverage, and lifecycle management tracking.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Looking for more products Product Finder
